trending Market Intelligence /marketintelligence/en/news-insights/trending/JIEc6fNXjMvkZXP5BwRZWA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Foamix, LEO Pharma settle patent dispute with Teva over Finacea topical foam

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Foamix, LEO Pharma settle patent dispute with Teva over Finacea topical foam

Foamix Pharmaceuticals Ltd. and LEO Pharma A/S settled a patent litigation with Petah Tikva, Israel-based Teva Pharmaceutical Industries Ltd. regarding Finacea foam, a topical treatment for a chronic skin disease.

Foamix did not disclose terms of the settlement agreement, which is is subject to the review of the U.S. Federal Trade Commission and the U.S. Department of Justice.

Foamix granted Ballerup, Denmark-based Leo Pharma a license to market Finacea foam, whose active ingredient is azelaic acid. Finacea treats inflammatory papules, or raised spots, and pimple-like bumps caused by rosacea — a common condition that causes persistent redness over the face and nose.

In April, Rehovot, Israel-based Foamix settled a patent dispute regarding Finacea with Perrigo Co. PLC, a Dublin-based maker of generic drugs. Foamix said it will pursue patent infringement litigation involving Finacea against Taro Pharmaceutical Industries Ltd. and its U.S. unit.